Introduction: COVID-19-associated coagulopathy includes systemic and endothelial inflammation with coagulation dysregulation related to immunothrombosis. The aim of this study was to characterize this complication of SARS-CoV-2 infection in patients with moderate to severe COVID-19.

Methods: An open-label, prospective observational study conducted in patients with COVID-19 moderate to severe acute respiratory failure admitted to an intensive care unit (ICU). Coagulation testing, including thromboelastometry, biochemical analysis and clinical variables, were collected at prespecified time points during the 30 days of ICU stay.

Results: The study included 145 patients, 73.8% male, with a median age of 68 years (interquartile range - IQR 55 - 74). The most prevalent comorbidities were arterial hypertension (63.4%), obesity (44.1%) and diabetes (22.1%). Simplified acute physiology score II (SAPS II) was on average 43.5 (11 - 105) and sequential organ failure assessment (SOFA) at admission was 7.5 (0 - 14). During ICU stay, 66.9% of patients underwent invasive mechanical ventilation and 18.4% extracorporeal membrane oxygenation support; thrombotic and hemorrhagic events occurred in 22.1% and 15.1% of the patients respectively; anticoagulation with heparin was present in 99.2% of patients since early ICU stay. Death occurred in 35% of patients. Longitudinal studies revealed changes in almost all coagulation tests during the ICU stay. SOFA score, lymphocyte counts, some biochemical, inflammatory and coagulation parameters, including hypercoagulability and hypofibrinolysis seen in thromboelastometry, differed significantly (p < 0.05), between ICU admission and discharge. Hypercoagulability and hypofibrinolysis persisted throughout ICU hospitalization, showing higher incidence and severity in non-survivors.

Conclusion: COVID-19-associated coagulopathy is characterized by hypercoagulability and hypofibrinolysis from ICU admission, and persisted throughout the clinical course in severe COVID-19. These changes were more pronounced in patients with higher disease burden and in non-survivors.

Download full-text PDF

Source
http://dx.doi.org/10.20344/amp.19475DOI Listing

Publication Analysis

Top Keywords

covid-19-associated coagulopathy
12
icu stay
12
hypercoagulability hypofibrinolysis
12
prospective observational
8
patients
8
moderate severe
8
icu
8
icu admission
8
study
5
coagulopathy characterization
4

Similar Publications

Background COVID-19 disease has caused a major global impact on health and mortality. This infection may predispose patients to thrombotic disease, caused by excessive inflammation, endothelial dysfunction, platelet activation, and stasis. In this study, we compared mortality rates in patients admitted to the hospital with the diagnosis of COVID-19, who also had the additional diagnosis of thrombosis with those who did not have thrombosis as an additional diagnosis.

View Article and Find Full Text PDF

This editorial article is intended to perform a discussion on the manuscript entitled "Simultaneous portal vein thrombosis and splenic vein thrombosis in a COVID-19 patient: A case report and review of literature" written by Abramowitz . The article focuses on the diagnostic processes in a 77-year-old-male patient with a simultaneous portal vein and splenic artery thrombosis accompanying coronavirus disease 2019 (COVID-19). The authors postulated that splanchnic thrombosis should be on the list of differential diagnoses in a patient presenting with abdominal pain in presence of a COVID-19 infection.

View Article and Find Full Text PDF
Article Synopsis
  • COVID-19 can lead to multiorgan issues, including thrombotic microangiopathy (TMA), which we studied in eight patients at our center.
  • Most patients showed few COVID-19 symptoms, and TMA occurred after the virus was present in their system; two had additional non-COVID-related factors triggering TMA.
  • Treatments varied based on the type of TMA, with some achieving recovery in blood and kidney functions, highlighting the need for tailored treatment approaches due to different causes and responses.
View Article and Find Full Text PDF

Investigation of ADAMTS-13 levels in patients with COVID-19 infection.

J Infect Dev Ctries

September 2024

Department of Pediatric Hematology and Oncology, Faculty of Medicine, Usak University, Usak, Turkiye.

Article Synopsis
  • COVID-19 patients have a higher risk of blood clotting issues, possibly linked to ADAMTS-13 levels, a protein that helps regulate blood clotting.
  • A study on 180 patients categorized them into mild and severe COVID-19 groups, comparing their ADAMTS-13 levels with a control group, using various clinical tests.
  • Results showed no significant differences in ADAMTS-13 levels between the groups, suggesting that it may not be a reliable biomarker for assessing patient risk upon admission.
View Article and Find Full Text PDF
Article Synopsis
  • * An analysis of 44,816 hospitalizations revealed that 90% of cases were likely attributable to COVID-19, particularly focusing on admissions from July 2022 to September 2023, where 86% were linked to COVID-19-related symptoms and treatments.
  • * The research found that younger adults and those without underlying health conditions were less likely to have COVID-19-attributable hospitalizations, suggesting that severe cases are more prevalent in older patients and those with pre-existing health issues.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!